For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.
Assistant Scientist I
At our world class facility in Elphinstone, Tranent (close to Edinburgh), our Environmental Fate and Metabolism department currently has an exciting career opportunity for an Assistant Scientist.
- Set up and maintenance of test systems
- Application of wet chemistry (solvent extraction, sample concentration and purification) and chromatographic techniques (TLC, HPLC) to investigate the metabolism and fate of pharmaceuticals, animal health products and agrochemicals in mammalian and / or environmental test systems.
- Compiling results summaries and communicating these effectively to other scientists
Applicants should have:
- Excellent communication skills
- An Honours degree or equivalent in chemistry or a life science subject with a chemistry related component.
- An enthusiastic approach to science
- Experience in analytical techniques (e.g. sample processing and chromatography) would be an advantage although not essential since training will be provided.
- Experience in the use of radioisotopes would be advantageous but not essential since training will be provided
Salary banding for this position is £21,101 Successful candidates will be appointed to the bottom of the pay band if they have no relevant experience.
In exceptional circumstances where the candidate has relevant equivalent experience, this will be taken into consideration.
Closing date: 6 June 2019
About Safety Assessment
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market. Each year approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 14,000 employees within 80 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2018, revenue increased by 22% to $2.27 billion from $1.86 billion in 2017.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2018.